Table 4.
Vaccine effectiveness of BNT162b2 against hospitalisation with Delta (B.1.617.2) and Omicron (B.1.1.529) variant by time since last vaccination.
| Characteristic | All adults |
<50 years |
≥50 years |
≥75 years |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VE (95% CI) | OR (95% CI) | P-value | VE (95% CI) | OR (95% CI) | P-value | VE (95% CI) | OR (95% CI) | P-value | VE (95% CI) | OR (95% CI) | P-value | |
| Delta variant | ||||||||||||
| Two doses ≤3 months - Unadjusted vaccine effectiveness | ||||||||||||
| Two doses | 96.5 (93.4–98.3) | 0.035 (0.017–0.066) | <0.001 | 94.0 (82.4–98.6) | 0.060 (0.014–0.176) | <0.001 | 96.3 (92.2–98.6) | 0.037 (0.014–0.078) | <0.001 | 97.0 (90.1–99.5) | 0.030 (0.005–0.099) | <0.001 |
| Two doses ≤3 months - Adjusted vaccine effectiveness (Logistic regression model) | ||||||||||||
| Two doses | 91.5 (83.1–96.2) | 0.085 (0.038–0.169) | <0.001 | 94.2 (82.1–98.7) | 0.058 (0.013–0.179) | <0.001 | 83.7 (61.8–94.1) | 0.163 (0.059–0.382) | <0.001 | 88.8 (55.5–98.3) | 0.112 (0.017–0.445) | 0.006 |
| Age | 1.012 (0.998–1.027) | 0.10 | 1.053 (1.023–1.085) | <0.001 | 0.985 (0.962–1.009) | 0.2 | 0.993 (0.936–1.053) | 0.8 | ||||
| Sex (male) | 1.319 (0.966–1.805) | 0.082 | 1.367 (0.847–2.212) | 0.2 | 1.070 (0.690–1.660) | 0.8 | 1.075 (0.496–2.331) | 0.9 | ||||
| CCI | 0.703 (0.613–0.801) | <0.001 | 0.707 (0.485–1.024) | 0.066 | 0.773 (0.661–0.894) | <0.001 | 0.810 (0.617–1.035) | 0.11 | ||||
| IMD | 0.994 (0.940–1.052) | 0.8 | 0.983 (0.904–1.070) | 0.7 | 1.027 (0.949–1.112) | 0.5 | 0.922 (0.806–1.051) | 0.2 | ||||
| Prevalence | 1.002 (1.001-1.002) | <0.001 | 1.001 (1.000–1.002) | 0.016 | 1.002 (1.001-1.003) | <0.001 | 1.002 (1.000–1.004) | 0.027 | ||||
| Week | 1.075 (1.052–1.099) | <0.001 | 1.036 (1.005–1.070) | 0.024 | 1.116 (1.080–1.155) | <0.001 | 1.100 (1.042–1.166) | <0.001 | ||||
| Two doses >3 months - Unadjusted vaccine effectiveness | ||||||||||||
| Two doses | 86.3 (82.0–89.7) | 0.137 (0.103–0.180) | <0.001 | 92.3 (79.6–97.8) | 0.077 (0.022–0.204) | <0.001 | 81.2 (74.5–86.3) | 0.188 (0.137–0.255) | <0.001 | 71.4 (55.3–81.7) | 0.286 (0.183–0.447) | <0.001 |
| Two doses >3 months - Adjusted vaccine effectiveness (Logistic regression model) | ||||||||||||
| Two doses | 79.5 (71.5–85.3) | 0.205 (0.147–0.285) | <0.001 | 94.6 (84.4–98.5) | 0.054 (0.015–0.156) | <0.001 | 74.6 (63.4–82.5) | 0.254 (0.175–0.366) | <0.001 | 66.8 (45.4–79.8) | 0.332 (0.202–0.546) | <0.001 |
| Age | 1.004 (0.992–1.015) | 0.5 | 1.062 (1.031–1.094) | <0.001 | 0.989 (0.972–1.007) | 0.2 | 0.987 (0.949–1.025) | 0.5 | ||||
| Sex (male) | 1.301 (0.997–1.700) | 0.053 | 1.301 (0.804–2.107) | 0.3 | 1.148 (0.822–1.605) | 0.4 | 1.030 (0.637–1.666) | >0.9 | ||||
| CCI | 0.806 (0.729–0.887) | <0.001 | 0.672 (0.462–0.959) | 0.031 | 0.864 (0.776–0.956) | 0.006 | 0.896 (0.767–1.036) | 0.2 | ||||
| IMD | 0.974 (0.929–1.022) | 0.3 | 1.015 (0.934–1.105) | 0.7 | 0.961 (0.904–1.020) | 0.2 | 0.898 (0.826–0.975) | 0.011 | ||||
| Prevalence | 1.001 (1.001-1.002) | <0.001 | 1.001 (1.000–1.003) | 0.009 | 1.001 (1.000–1.002) | 0.003 | 1.001 (1.000–1.002) | 0.051 | ||||
| Week | 1.090 (1.069–1.112) | <0.001 | 1.034 (1.002–1.068) | 0.038 | 1.125 (1.095–1.156) | <0.001 | 1.138 (1.093–1.187) | <0.001 | ||||
| Omicron variant | ||||||||||||
| Three doses ≤ 3 months - Unadjusted vaccine effectiveness | ||||||||||||
| Three doses | −49.8 (−130.8–2.8) | 1.498 (0.972–2.308) | 0.066 | −85.4 (−385.8–27.5) | 1.854 (0.725–4.858) | 0.2 | −44.2 (-136–12) | 1.442 (0.880–2.360) | 0.14 | −64.8 (−206.1–10.8) | 1.648 (0.892–3.061) | 0.11 |
| Three doses ≤ 3 months - Adjusted vaccine effectiveness (Logistic regression model) | ||||||||||||
| Three doses | 31.0 (−15.3–59.1) | 0.690 (0.409–1.153) | 0.2 | 13.3 (−158.2–71) | 0.867 (0.290–2.582) | 0.8 | 41.1 (−7.4–68.2) | 0.589 (0.318–1.074) | 0.087 | 50.8 (−12.2–79.2) | 0.492 (0.208–1.122) | 0.10 |
| Age | 1.002 (0.988–1.016) | 0.8 | 1.034 (0.990–1.081) | 0.13 | 0.999 (0.975–1.023) | >0.9 | 1.026 (0.970–1.086) | 0.4 | ||||
| Sex (male) | 0.953 (0.650–1.398) | 0.8 | 0.586 (0.284–1.189) | 0.14 | 1.197 (0.742–1.935) | 0.5 | 1.584 (0.811–3.115) | 0.2 | ||||
| CCI | 0.972 (0.856–1.102) | 0.7 | 0.756 (0.469–1.146) | 0.2 | 1.016 (0.885–1.167) | 0.8 | 1.092 (0.904–1.334) | 0.4 | ||||
| IMD | 1.065 (0.995–1.141) | 0.069 | 1.179 (1.042–1.341) | 0.010 | 1.018 (0.935–1.108) | 0.7 | 1.036 (0.916–1.173) | 0.6 | ||||
| Prevalence | 1.002 (1.001-1.002) | <0.001 | 1.001 (1.000–1.003) | 0.026 | 1.002 (1.001-1.002) | <0.001 | 1.002 (1.001-1.003) | <0.001 | ||||
| Week | 0.955 (0.915–0.995) | 0.030 | 0.958 (0.890–1.030) | 0.3 | 0.956 (0.907–1.007) | 0.094 | 0.931 (0.858–1.007) | 0.079 | ||||
| Three doses >3 months - Unadjusted vaccine effectiveness | ||||||||||||
| Three doses | 40.4 (21.3–55.0) | 0.596 (0.450–0.787) | <0.001 | 62.1 (18.7–83.8) | 0.379 (0.162–0.813) | 0.017 | 36.6 (12.9–53.9) | 0.634 (0.461–0.871) | 0.005 | 41.7 (12.3–61.2) | 0.583 (0.388–0.877) | 0.009 |
| Three doses >3 months - Adjusted vaccine effectiveness (Logistic regression model) | ||||||||||||
| Three doses | 33.9 (8.4–52.4) | 0.661 (0.476–0.916) | 0.013 | 57.0 (−4.9–83.6) | 0.430 (0.164–1.049) | 0.072 | 31.7 (2.4–52.3) | 0.683 (0.477–0.976) | 0.036 | 46.9 (16.3–66.4) | 0.531 (0.336–0.837) | 0.006 |
| Age | 1.002 (0.991–1.014) | 0.7 | 1.026 (0.987–1.068) | 0.2 | 0.994 (0.976–1.012) | 0.5 | 1.008 (0.972–1.045) | 0.7 | ||||
| Sex (male) | 1.010 (0.750–1.360) | >0.9 | 0.656 (0.326–1.294) | 0.2 | 1.097 (0.782–1.539) | 0.6 | 1.406 (0.921–2.158) | 0.12 | ||||
| CCI | 0.955 (0.868–1.047) | 0.3 | 0.867 (0.576–1.253) | 0.5 | 0.967 (0.875–1.067) | 0.5 | 0.987 (0.876–1.109) | 0.8 | ||||
| IMD | 1.016 (0.964–1.071) | 0.5 | 1.159 (1.030–1.309) | 0.016 | 0.987 (0.929–1.048) | 0.7 | 0.995 (0.924–1.073) | >0.9 | ||||
| Prevalence | 1.001 (1.001-1.002) | <0.001 | 1.001 (1.000–1.002) | 0.2 | 1.001 (1.001-1.002) | <0.001 | 1.001 (1.001-1.002) | <0.001 | ||||
| Week | 0.970 (0.937–1.004) | 0.084 | 0.944 (0.878–1.011) | 0.10 | 0.980 (0.941–1.021) | 0.3 | 0.961 (0.911–1.014) | 0.15 | ||||
CI, Confidence Interval; CCI, Charlson comorbidity index; FiO2, Fraction inspired oxygen; IMD, index of multiple deprivation; OR, Odds Ratio; VE, vaccine effectiveness; WHO, World Health Organisation.
The results of Matched Conditional Logistic Regression models are shown in Supplementary Data 4.